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Steatosis1. BackgroundIn this issue of EBioMedicine, Roerecke and Colleagues report that, in
Japan, alcohol consumption as low as b20 g daily was associated with
significant protection from incident and prevalent fatty liver; however,
no such association was found in countries other than Japan (Roerecke
et al., 2016). This systematic review is based on the analysis of 18
articles (11 of which are from Japan) which recruited, overall, 99,370
participants, 25,662 of whom had steatosis.
Moreover, sex was an important modifier of the risk of fatty liver
when the whole range of alcohol consumption was considered. Indeed,
while in men a non-linear and inverse dose-response risk relationship
was reported, in women the risk curve was J-shaped and turned to a
detrimental association with increasing alcohol consumption.
Finally, binge drinking was consistently associated with higher risk
of liver steatosis.
2. Steatosis
Steatosis defines fatty changes either in N5% of hepatocytes based on
histological analysis or N5.6% based on findings from proton magnetic
resonance spectroscopy (EASL-EAS-EASO, 2016). Often, steatosis is di-
agnosed with ultrasonography both in clinical practice and in the re-
search arena (Ballestri et al., 2015, 2016a).
A large variety of causes, notably including alcohol consumption,
may eventually be conducive to accumulation of intrahepatic fat
(EASL-EAS-EASO, 2016). In recent years nonalcoholic fatty liver disease
(NAFLD) has reached massive proportions worldwide and has an epi-
demic diffusion in certain high-risk groups. However, the rationale forDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.04.023.
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questioned based on shared clinico-pathological commonalities
(Völzke, 2012).3. Relationship of Fatty Liver with the Metabolic Syndrome
Traditionally deemed to be the “hepaticmanifestation of themetabolic
syndrome”, NAFLD is more correctly deemed to be bi-directionally
linked with either the Metabolic Syndrome (MetS) or its individual
components. Indeed, on the one hand metabolic derangements are a
strong predictor of all the individual histological components of
NAFLD (Ballestri et al., 2016b). On the other hand, NAFLD assessed
with either liver enzymes or ultrasonography will predict the risk of in-
cident MetS and type 2 diabetes (T2D) over 5 years (Ballestri et al.,
2016a).4. Relationship of Alcohol with MetS
Alcohol consumption exerts a complex effect on theMetS with light
alcohol consumption reducing and heavy alcohol consumption increas-
ing the risk of MetS (Sun et al., 2014). Consistently, a randomized
controlled trial in 224 individuals reported that initiating moderate
consumption of alcohol (particularly red wine) modestly decreased
cardiometabolic risk in patients with well controlled T2D (Gepner
et al., 2015).5. How Little Alcohol Is Safe?
A consensus report concluded that the threshold of acceptability in
healthy adults/elderly was ≤30 g ethanol daily for men and ≤15 g
daily for women (Poli et al., 2013). Such a modest amount of alcohol
does not necessitate any medical action (Poli et al., 2013). This study
confirms that, irrespective of sex, alcohol b20 g daily is probably safe.
In men the threshold of safety may even be higher, whereas women
are more vulnerable and develop more severe toxicity for lower
amounts of alcohol. This is of interest given that the drinking of moder-
ate amounts of red wine regularly is probably associated with a relative
health benefit thanks to antioxidants such as polyphenols, particularly
resveratrol.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Interestingly, findings from this study would suggest that the bene-
ficial effect of modest alcohol consumption is restricted to Japan, and is
not extended to other countries (the Japanese paradox). This conclusion
may, though, be spurious given that quantity and quality of data vary
across countries and are probably non-comparable. Alternatively,
types of alcoholic beverages and pattern of alcohol consumption in
Japan or interaction of host's metabolic factors (notably including
obesity) may account for this discrepancy (Askgaard et al., 2015). Of
note, binge drinking was consistently associated with increased risk of
fatty liver across countries, suggesting that this pattern of alcohol
consumption is universally harmful.
7. Conclusions
To sum up, the study by Roerecke et al. (2016) confirms, in Japanese
individuals, that modest alcohol consumption does not exert any
detrimental effects in healthy individuals. In this specific setting, it may
even have beneficial effects by decreasing incidence and prevalence of
steatosis. Future studies should evaluate the reasons why such benefits
are not reproducible outside Japan, namely the Japanese paradox.
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